PLoS ONE (Jan 2022)

Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21

  • Ruth K. Lucinde,
  • Daisy Mugo,
  • Christian Bottomley,
  • Angela Karani,
  • Elizabeth Gardiner,
  • Rabia Aziza,
  • John N. Gitonga,
  • Henry Karanja,
  • James Nyagwange,
  • James Tuju,
  • Perpetual Wanjiku,
  • Edward Nzomo,
  • Evans Kamuri,
  • Kaugiria Thuranira,
  • Sarah Agunda,
  • Gideon Nyutu,
  • Anthony O. Etyang,
  • Ifedayo M. O. Adetifa,
  • Eunice Kagucia,
  • Sophie Uyoga,
  • Mark Otiende,
  • Edward Otieno,
  • Leonard Ndwiga,
  • Charles N. Agoti,
  • Rashid A. Aman,
  • Mercy Mwangangi,
  • Patrick Amoth,
  • Kadondi Kasera,
  • Amek Nyaguara,
  • Wangari Ng’ang’a,
  • Lucy B. Ochola,
  • Emukule Namdala,
  • Oscar Gaunya,
  • Rosemary Okuku,
  • Edwine Barasa,
  • Philip Bejon,
  • Benjamin Tsofa,
  • L. Isabella Ochola-Oyier,
  • George M. Warimwe,
  • Ambrose Agweyu,
  • J. Anthony G. Scott,
  • Katherine E. Gallagher

Journal volume & issue
Vol. 17, no. 10

Abstract

Read online

Introduction The high proportion of SARS-CoV-2 infections that have remained undetected presents a challenge to tracking the progress of the pandemic and estimating the extent of population immunity. Methods We used residual blood samples from women attending antenatal care services at three hospitals in Kenya between August 2020 and October 2021and a validated IgG ELISA for SARS-Cov-2 spike protein and adjusted the results for assay sensitivity and specificity. We fitted a two-component mixture model as an alternative to the threshold analysis to estimate of the proportion of individuals with past SARS-CoV-2 infection. Results We estimated seroprevalence in 2,981 women; 706 in Nairobi, 567 in Busia and 1,708 in Kilifi. By October 2021, 13% of participants were vaccinated (at least one dose) in Nairobi, 2% in Busia. Adjusted seroprevalence rose in all sites; from 50% (95%CI 42–58) in August 2020, to 85% (95%CI 78–92) in October 2021 in Nairobi; from 31% (95%CI 25–37) in May 2021 to 71% (95%CI 64–77) in October 2021 in Busia; and from 1% (95% CI 0–3) in September 2020 to 63% (95% CI 56–69) in October 2021 in Kilifi. Mixture modelling, suggests adjusted cross-sectional prevalence estimates are underestimates; seroprevalence in October 2021 could be 74% in Busia and 72% in Kilifi. Conclusions There has been substantial, unobserved transmission of SARS-CoV-2 in Nairobi, Busia and Kilifi Counties. Due to the length of time since the beginning of the pandemic, repeated cross-sectional surveys are now difficult to interpret without the use of models to account for antibody waning.